ArticleTherapeutic advances in gastroenterology2023
10 years of biologic use patterns in patients with inflammatory bowel disease: treatment persistence, switching and dose intensification - a nationwide population-based study.
Article in Therapeutic advances in gastroenterology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 15 citations in OpenAlex.
- Letter to the Editor: Can upadacitinib dose escalation redefine treatment strategies in refractory inflammatory bowel disease?World journal of gastrointestinal pharmacology and therapeutics · 2026Article
- Therapy Persistence and Dose Escalation of Advanced Treatments in First and Second Line of Ulcerative Colitis and Crohn's Disease - A Retrospective Cohort Analysis of Healthcare Claims Data.Zeitschrift fur Gastroenterologie · 2026Article
- A Comparative Study of Different Biological Drugs in First-Line Therapy in Crohn's Disease: A Multicenter Descriptive Analysis.Medicina (Kaunas, Lithuania) · 2026Article
- Real-world patterns of inflammatory bowel disease treatment across adult and pediatric populations: a nationwide cohort study in South Korea.Frontiers in medicine · 2026Article
- Real-Life Use of Subcutaneous Biologicals and JAK Inhibitors in IBD Maintenance Therapy: Treatment Continuation, Switching Patterns, and Concomitant Medications.Clinical and experimental gastroenterology · 2026Article
- Persistence of advanced therapies in patients with ulcerative colitis: real-world data from the nationwide CREdIT registry.Therapeutic advances in gastroenterology · 2026Article
- Ulcerative colitis: Timeline to a cure.World journal of gastroenterology · 2025Article
- Persistence of advanced therapies in patients with inflammatory bowel disease: retrospective cohort study using a large healthcare claims database in Japan.Intestinal research · 2025Article
- Temporal Trends in the Use of Biological Agents in Patients with Inflammatory Bowel Disease: Real-World Data from a Tertiary Inflammatory Bowel Disease Greek Center During a 5-Year Period.Journal of clinical medicine · 2025Article
- Effectiveness of ustekinumab in Crohn's disease across intestinal locations: spotlight on isolated small intestinal involvement.Therapeutic advances in gastroenterology · 2025Article
- Comparative real-world outcomes between ustekinumab, infliximab, and adalimumab in bio-naïve and bio-experienced Crohn's disease patients: a retrospective multicenter study.BMC gastroenterology · 2024Article
- Treatment trajectories and outcomes in inflammatory bowel disease: a tertiary single-centre experience.Therapeutic advances in gastroenterology · 2024Article
- Comment on: [10 years of biologic use patterns in patients with inflammatory bowel disease: treatment persistence, switching and dose intensification - a nationwide population-based study].Therapeutic advances in gastroenterology · 2024Article
- Patterns and factors associated with dose escalation during maintenance treatment for inflammatory bowel disease: a population-based cohort study.Sage open chronic diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Treatments for inflammatory bowel diseases (IBD) have evolved in the era of biologics. However, the real-world data on their usage patterns and sequencing are still limited. Objectives: We aimed to investigate treatment persistence and dose intensification of first- and second-line biologics in patients with IBD. Design: In this retrospective, cohort study using nationwide claims data, 13,087 patients with IBD initiating biologic therapy between 2010 and 2020 were identified. Methods: Treatment persistence and dose intensification during the first 2 years and switching patterns of biologics were analysed while identifying predictors of non-persistence. Results: As a first-line treatment of Crohn's disease (CD), ustekinumab had a lower risk for non-persistence compared to infliximab [adjusted hazard ratio (aHR), 0.69, Conclusion: Ustekinumab had higher persistence in the first-line treatment of CD, while golimumab had lower persistence for first- and second-line treatments of UC. Dose intensification rates varied, with the highest cumulative rates observed for ustekinumab in CD and adalimumab in second-line UC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.